Skip to content

Specialties
Clinical Updates
Medical News
iDoctor

Specialties
Clinical Updates
Medical News
iDoctor

Search for:

facebook.com
twitter.com
t.me
instagram.com
youtube.com

TrialNet

Home
TrialNet

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Posted inDiabetes & Endocrinology Immunology news

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Posted by

By MedXY 06/15/2026

Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.

口服司美格鲁肽心血管获益再添证据：SOUL 研究提示高危 2 型糖尿病患者 MACE 风险下降
Restoring Cortisol Rhythm May Be Key to Recovery After Cushing Syndrome
Long-term Follow-up of Type 1 Diabetes Immunotherapy Trials Finds Reassuring Safety Signals
Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.

Sign in